




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof

Further quantitative *in silico* analysis of SARS-CoV-2 S-RBD Omicron BA.4, BA.5, BA.2.75, BQ.1, and BQ.1.1 transmissibility

Toshihiko Hanai



PII: S0039-9140(22)00923-7

DOI: <https://doi.org/10.1016/j.talanta.2022.124127>

Reference: TAL 124127

To appear in: *Talanta*

Received Date: 4 October 2022

Revised Date: 15 November 2022

Accepted Date: 21 November 2022

Please cite this article as: T. Hanai, Further quantitative *in silico* analysis of SARS-CoV-2 S-RBD Omicron BA.4, BA.5, BA.2.75, BQ.1, and BQ.1.1 transmissibility, *Talanta* (2022), doi: <https://doi.org/10.1016/j.talanta.2022.124127>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


© 2022 Published by Elsevier B.V.

CRedit author statement for the manuscript:

Further quantitative *in silico* analysis of SARS-CoV-2 S-RBD Omicron BA.4, BA.5, BA.2.75, BQ.1, and BQ.1.1 transmissibility

Toshihiko Hanai, Health Research Foundation, Research Institute for Production Development 4F, Sakyo-Ku, Kyoto, 606-0805

Mutation to basic amino acids enhanced the binding affinity of S-RBD with ACE-2 by ion-ion interaction. The mutated lysine and arginine of Omicron BA.2 mutant are circled. The binding strength is related to the number of mutated basic amino acids and steric hindrance affects the binding affinity, too. Carboxy acid-bound S-RBD was repulsed from the ACE-2 binding site where many acidic amino acids lined up. Mutated S-RBD amino acids and ACE-2 several acidic amino acids are indicated.



Further quantitative *in silico* analysis of SARS-CoV-2 S-RBD Omicron BA.4, BA.5, BA.2.75, BQ.1, and BQ.1.1 transmissibility

Toshihiko Hanai, Health Research Foundation, Research Institute for Production Development
4F, Sakyo-Ku, Kyoto, 606-0805

hanai104@kf7.so-net.ne.jp

ABSTRACT

The Covid-19 variants' transmissibility was further quantitatively analyzed *in silico* to study the binding strength with ACE-2 and find the binding inhibitors. The molecular interaction energy values of their optimized complex structures (MIFS) demonstrated that Omicron BA.4 and 5's MIFS value (344.6 kcal·mol⁻¹) was equivalent to wild-type MIFS (346.1 kcal·mol⁻¹), that of Omicron BQ.1 and BQ. 1.1's MIFS value (309.9 and 364.6 kcal·mol⁻¹). Furthermore, the MIFS value of Omicron BA.2.75 (515.1 kcal·mol⁻¹) was about Delta-plus (511.3 kcal·mol⁻¹). The binding strength of Omicron BA.4, BA. 5, and BQ.1.1 may be neglectable, but that of Omicron BA.2.75 was urging. Furthermore, the 79 medicine candidates were analyzed as the binding inhibitors from binding strength with ACE-2. Only carboxy compounds were repulsed from the ACE-2 binding site indicating that further modification of medical treatment candidates may produce an effective binding inhibitor.

Keywords: SARS-CoV-2 Omicron variants (BA.4, BA.5, BA.2.75, BQ.1, BQ.1.1), ACE-2, Binding strength, Quantitative *in silico* analysis, Molecular interaction energy, Binding inhibitor,

1. Introduction

Once the death numbers soared by Omicron BA.1 and BA.2 in the last winter; then, new mutants, Omicron BA.4 and BA.5, appeared, and the death numbers declined to be compatible with the influenza death numbers. Several countries announced that the disease was not to be pandemic. The definition of the pandemic is not clear, but the disease was defined as not a pandemic but a syndemic [1-4]. But we are still fighting to control Covid-19 infection. The mutants Omicron BA.2, BA.4, and BA.5 are listed as variants of concern, and omicron BA.2.75 and BQ.1 is considered a variant of interest [5]. The SARS-Cov-2 infection mechanism was described in detail, and the target approach was proposed [6]; however, the solution is far from conclusive. The mutation of viruses is too fast, and the development of new vaccines and medicines is far behind. Previous infection with an older variant such as Alpha, Beta, or Delta offers some protection against reinfection with Omicron BA.4 and BA.5 [7]. This may be a similar mutation of the Omicron BA.4 and BA.5 S-RBD binding site to that of the older variants and different from that of Omicron BA.1 and BA.2, in which various amino acids are mutated.

Furthermore, Omicron BA4 and BA.5 showed reduced neutralization by the serum from individuals vaccinated with triple doses of AstraZeneca or Pfizer vaccine compared with Omicron BA.1 and BA.2. In

addition, using the serum from Omicron BA.1 vaccine breakthrough infections, there were significant reductions in the neutralization of Omicron BA.4 and BA.5 whose multiplication extend beyond that to other variants [8], raising the possibility of repeat Omicron infections. A greater escape from neutralization of Omicron BA.4 and BA.5 compared with Omicron BA.1 and BA.2 was reported [8]. Serum from triple-vaccinated donors had a 2 to 3-fold reduction in neutralization titers compared with the neutralization of Omicron BA.1 and BA.2. The prevention of transmission might become less effective as viruses evolve antigenically further from ancestral strains. While vaccination was unlikely to eliminate transmission, the combination of vaccines with boosting by natural infection will probably continue to protect the majority from severe disease. The L452R and F486V mutations both made major contributions to Omicron BA.4 and BA.5 escape. [9] However, the L452R mutation strengthens the binding with ACE-2 based on previous analysis. One emerging sublineage Omicron BA.2.75, which might escape from antibodies due to the mutation, did not show greater antibody evasion than Omicron BA.5 [10]. A different approach to drug discovery was proposed and created minimal virions of wild-type (WT) and mutant SARS-CoV-2 with precise molecular composition and programmable complexity by the bottom-up assembly to study the free fatty acid binding pocket that was an allosteric regulatory site enabling adaptation of SARS-CoV-2 immunogenicity to inflammation states via binding of pro-inflammatory free fatty acids. Vitamin K and dexamethasone might work in the pocket instead of fatty acids; therefore, the approach may find a future COVID-19 therapy [11]. Drug resistance to Nirmatrelvir (Paxlovid) of SARS-Cov-2 protease mutants was extensively studied. The mutation around the binding site reduced enzyme activity [12]. The mutation prevented antibody binding and neutralization. The antibodies almost always interacted with the amino acid at position K417N or E484A [13]. The original amino acid K417 is the key mutation amino acid; the mutation to neutral amino acid reduces the S-RBD binding strength with ACE-2. The S-RBD E484 is repulsed from ACE-2; therefore, the E484A mutation erases the repulsion from ACE-2. R493 and R498 of S-RBD demonstrated their binding with ACE-2 via ion-ion interaction [14]. This fact supported the previous observation [15].

On the other hand, monoclonal antibodies have been considered to prevent the virus from infecting human cells by binding to the virus's spike protein; however, Omicron is totally or partially resistant to all currently available monoclonal antibodies [16]. Another report using lentivirus-based pseudo virus demonstrated that Bamlanivimab, Casirivimab, Etesevimab, Imdevimab, and Tixagevimab were less functional against BA.2 but Bebtelovimab, Cilgavimab, Imdevimab, Sotrovimab demonstrated a little effectiveness for neutralizing Omicron BA.1 and BA.2 variants [17]. Bebtelovimab showed remarkable preserved *in vitro* activity against all SARS-CoV-2 variants, including Omicron BA.4 and BA.5 [18]. The monoclonal antibody may bind to the S-RBD for protection; however, the binding with ACE-2 has not been described in detail.

Previously, the MI of their optimized complex structures demonstrated that Omicron BA.2's MIFS value was 1.4 times Delta MIFS and 2.7 times Alfa MIFS. The Omicron BA.2 S-RBD demonstrated the most vital transmissible strength [15]. The 14 currently proposed medical treatment compounds did not show as the inhibitors to block the Omicron S-RBD and ACE-2 binding. Despite the availability of vaccines and

medicines, the infection has not been under control, and Omicron infections are high as ever. Therefore, further study was carried out transmissibility of Omicron BA.4 and BA.5, BA.2.75, BQ.1, and BQ.1.1 as the difference in molecular interaction energy values. Additional 79 binding inhibitor candidates were analyzed *in silico* by calculating binding strength with ACE-2.

2. Experimental

The manual docking process was the same as that used previously [15]. The basic complex structure of SARS-CoV-2 and ACE-2 was from reference [19]. The amino acids of the extracted S-RBD were mutated based on the reference [5], and the mutated structures were optimized using the MM2 program. The mutated S-RBD was superimposed on the original reference structure; then, the new S-RBD and ACE-2 formed a complex in the optimization process. The MI energy values were obtained from their original and the complex's values using the following equation: $MIFS = \{f_s(\text{S-RBD}) + f_s(\text{ACE-2})\} - FS(\text{S-RBD and ACE-2 complex})$, where f_s is the final structure energy value of individual molecule, and FS is the final structure energy value of the complex. HB, ES, and VW indicate the final (optimized) structure, hydrogen bonding, electrostatic interaction, and van der Waals force.

Computational chemical calculations were performed using a DCPIx86-based PC with an Intel Core™i7-2600 cpu 3.40 GHz (Dospa, Yokohama) with the CAChe program (Fujitsu, Tokyo). The minimum energy level was 10^{-7} kcal mol⁻¹.

3. Results and Discussion

The strongest molecular interaction force is ion-ion interaction; mutations of acidic and/or neutral amino acids to basic amino acids of Covid-19 S-RBD enhanced the binding strength with ACE-2 binding [20], and such mutation hiked the transmissibility of Covid-19 mutants. The typical mutations are E484K, L452R, T478K, Q493R, and Q498R. Once the Delta valiant panicked us with the stronger transmissibility. Delta's only two mutations of the S-RBD (L452R and T478K) enhanced the MIFS value 1.71 times that of WT S-RBD. Increased numbers of basic amino acids (arginine, lysin) tighten the binding via ion-ion interaction. MIES energy contributes 72% of the binding force of Delta. Furthermore, Omicron BA.1 valiant with 15 mutants (G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H) exhibits the stronger binding force with ACE-2. In addition, Omicron BA.2 valiant with 16 mutants (G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H) demonstrates the strongest binding force. The four mutants to basic amino acids (N440K, T478K, Q493R, Q498R) contributed to their high MIFS energy values of Omicron BA.1 and BA.2, 761.7 and 904.3 kcal mol⁻¹, respectively. The ion-ion interaction is their main mechanism, and their MIES values contributed 63.7 % of their interaction energy value.

However, variants Omicron BA.4 and BA.5 have become widely spread viruses. Their S-RBD mutations are the same. Only two mutations actually happened, and the primary mutant is L452R. The calculated MIFS energy value is 344.6 kcal mol⁻¹, and the value is similar to that of W.T. The binding strength is neglectable, but the simple mutation may speed up the multiplication. Another variant Omicron BA.2.75

actually has three mutants (D339H, G446S, N460K). The MIFS energy value was 515.1 kcal mol⁻¹, which was similar to that of the Delta-plus (511.3 kcal mol⁻¹). Recently, the variants Omicron BQ.1 and BQ.1.1, were emerged and were replacing Omicron BA.4 and BA.5. Their MIFS energy values were not high, and their basic amino acid K460 is far from the binding site with ACE-2. The spreading reason was considered based on their rapid multiplication [8]. The necessary complicated multi-mutation Omicron BA.1 and BA.2 variants may have weak multiplication; however, Omicron BA.2.75 should be carefully monitored not to spread like the Delta variant. The location of mutated amino acids of Delta, Omicron BA.2, Omicron BA.4, Omicron BA.2.75, Omicron BQ.1, and Omicron BQ.1.1 are indicated in Figure 1. These calculated MI values are summarized in Table 1. Figures of BA.2 and Delta B.1.617.2 are reference structures for their comparison.




Figure 1. Structure of ACE-2 complexes with S-RBD of Delta, Omicron BA.2 with ACE-2, BA.2.75, BA.4 (BA.5), BQ.1 and BQ.1.1.

Critical amino acid residues are indicated as 0.5 atomic sizes, and other amino acids are done as 0.02 atomic sizes. The location of ACE-2 aspartic acid (D) is indicated. Another acidic amino acid is glutamic (E). Black, dark gray, light gray, and white balls are oxygen, nitrogen, carbon, and hydrogen.

The Omicron BA.1 and BA.2 demonstrated the strongest binding affinity; however, the multiplication was expected slow, and our defense (immune) system should overcome the spreading. However, the Covid-19 virus changed its strategy and produced Omicron BA.4 and BA.5 variants (variants of concern) that mutate only three amino acids of S-RBD, and their multiplication speed is considered fast, and it became the main Covid-19 virus, now. Omicron BA.2.75 is recognized as a variant of interest due to its transmissibility.

Table 1 Molecular interaction energy values between ACE-2 and SARS-CoV-2 mutants

Mutant	MIFS	MIHB	MIES	MIVW
WT	346.0675	284.725	186.499	-58.491
Delta B.1.517.2	594.1785	321.588	426.310	-70.623
Delta-plus AY.1	511.2668	353.568	264.584	-53.387
Omicron BA.1	761.7122	389.186	484.065	-60.100
Omicron BA.2	904.3286	475.158	576.588	-73.122
Omicron BA.2.75	515.1229	288.025	282.777	-27.122
Omicron BA.4&5	344.6077	175.479	166.0875	-62.349
Omicron BQ.1	309.9460	248.473	97.942	-3.738
Omicron BQ.1.1	364.6182	300.761	114.112	-17.027

PDB 7kmb, Unit: kcal·mol⁻¹

The additional 79 inhibitor candidates were studied to determine whether they would inhibit the S-RBD binding with ACE-2. The calculated MIFS, MIHB, MIES, and MIVW values are summarized in Table 2.

Table 2. Molecular interaction values between an analyte and ACE-2

Compound [ref]	MIHB	MIES	MIVW	XlogP	logP*	pKa*
Absinthin [21]	24.991	4.611	19.358	2.2		
Aesculetin [22]	56.528	15.021	-3.040	-2		
Angelicin [22]	4.024	6.277	1.862	2	2.08(S)	
Artecanin [44]	-7.827	9.904	16.913	0.2		
Asperagenin [21]	42.577	25.362	13.564	3.9		
Aspirine- <i>O</i> -mannoside methylester	146.306	36.721	9.076			
Baicalin [23]	72.096	21.502	5.309	1.1		
Berberine [23]	19.849	7.162	15.118	3.6		
Bergapten [22]	61.680	13.776	3.624	2.3	1.93(E)	
Budesonide [28]	39.565	3.638	10.409	2.5	1.914(D)	
<i>m</i> -Carboxy- <i>L</i> -tyrosine methylester	-42.521	-36.950	25.828			
<i>m</i> -Carboxy- <i>L</i> -tyrosine methylester mannoside	-38.815	-37.112	28.540			
Carmofur [25]	32.058	8.183	-7.103	2.6	2.63(E)	
Carolacton (M) [29]	90.786	34.017	13.273	3.4		
Carolacton (I)	49.382	3.561	-3.051			
CHEMBL2171598 [28]	56.611	34.619	24.789	7.1		
Chloroquine [25, 31-33]	41.069	16.030	11.630			
Cinanserine [25]	93.928	46.517	-11.833	4.1		
Clofazimine [46]	-8.091	-24.558	21.147	7.1	7.66(D,E)	8.51(D)
Dalcetrapib [34]	-3.442	3.277	21.218	7.1		
Dasatinib [35]	59.391	4.710	21.513	3.6	1.8(D,HM)	
Deguelin [23]	29.416	22.198	15.848	3.7		
2,6-Deoxyactein [21]	40.586	3.839	24.837	3.9		
Dexamethasone [36]	178.940	44.341	-15.208	1.9	1.83(H)	
Disulfiram[25]	34.658	3.467	14.802	3.9	3.88	
Dolutegravir [37]	83.004	34.956	3.494	2.4	2.2	
Dorsilurin E [30]	195.398	-7.930	-17.266	3.9	3.88(H)	
Ebselen [25]	62.609	32.602	6.118	-		
EIDD-2801 [29],	113.580	44.426	2.170	-0.8		
Emetine [29]	47.286	1.543	4.784	4.7		5.77, 6.64(HS)
Emodin [25]	58.023	4.345	-1.169	2.7		
Etravirine [37]	-2.536	5.482	23.965	4.5		
Eugenol [23]	55.699	-4.692	10.954	2	2.27(E)	10.19(D)

Evodiamine [23]	13.125	7.648	11.834	3.1		
Favipiravir [25, 38-40]	-34.055	-32.693	16.672	-0.5		5.1(D)
Flavanone [48]	41.321	1.408	7.738			
Fluvoxamine [28,41]	43.850	10.628	-5.581	2.6	3.2(D)	
Fluoxetine [28]	7.449	4.715	15.166	4	4.05(D)-	
Hecogenin [21]	27.224	17.992	11.173	4.8		
Heraclenin [22]	10.100	3.894	18.997	2.2		
Heraclenol [22]	24.340	4.703	5.210	1.2		
Homoharringtonine						
(Omacetaxine mepesuccinate) [29]	85.605	65.102	7.787	0.8		
(2 <i>R</i> ,3 <i>S</i> ,4 <i>S</i> ,5 <i>S</i> ,6 <i>R</i>)-6-(Hydroxymethyl)-oxane-2,3,4,5-tetrol [25]	48.840	16.969	-9.645	-2.6		
2-Hydroxypropane-1,2,3-tricarboxylic acid (M) [25]	38.858	17.744	-2.030	-1.7		
2-Hydroxypropane-1,2,3-tricarboxylic acid (I)		repulsed				
Imperatorin [22]	56.808	23.858	4.483	3.4	2.983	
Indinavir [37, 41]	66.626	5.283	15.868	2.8	2.9(D),3.49(E)	
Kazinol-A [24]	50.404	64.987	6.795	6.6		
Kurarione [23]	39.696	3.256	10.240	5.6		
Laninamivir (Inavir) [39]	59.592	24.819	-3.599	-3.2		
Limonin [21]	-5.413	4.090	20.745	1.8		
Limonoid [42]	70.553	26.388	8.003			
Oleandrin [43]	5.989	-0.327	28.278	2.4	2.53(HS)	
Oxepeucedanin [22]	6.371	7.904	17.283	2.6	2.55(HS)	
Peramivir (Rapivab) [39]	37.872	25.813	13.216	0		
PGG (1,2,3,4,6-Penta- <i>O</i> -galloyl-β- <i>D</i> -glucose) [23]	106.966	17.225	-8.799	3.6		
Procyanidin [23]	83.264	24.991	-13.070	2		
Psoralen [22]	20.576	12.800	1.547	2.3	1.67(E)	
Quercetin-7- <i>O</i> -glucoside [23]	43.254	21.447	9.830	0.4		
Raltegravir [37]	68.484	32.632	-5.509	1.1	0.40 (HS)	
Resveratrol [26]	21.596	8.489	5.493	3.1	3.1(HS)	8.99,9.63,10.64(HS)
Ribavirin [25, 32]	53.518	23.421	8.328	-1.8	-1.85(D)	
SaikosaponinA [23]	54.456	25.843	14.237	2.5		
Saquinavir [35, 41]	133.586	58.456	5.561	4.2	3.8(D), 4.7(E)	
Sanggenol F [30]	21.400	20.625	14.030	F5.2		
Sanggenol L [30]	36.708	18.802	-5.954	L5.3		
Savinin [24],	-4.988	0.181	22.904	3.6		
Saxalin [22]	2.851	2.749	19.408	2.9		
Schizanthine Y[44]	-5.257	2.240	18.725	D2.8, A5.3		
Shizukaol A [21]	12.107	9.477	13.054	2.3		
Sildenafil [35]	10.306	2.023	27.418	1.5	1.9(D), 2.75€	
Tadalafil [35]	6.996	6.654	17.179	-		
Theaflavin-3,3-digallate [24]	63.911	28.390	21.023	3.2		
Tideglusib [25]	15.821	8.800	21.432	4.3	3.28(D)	
Timosaponin A-1 [21]	34.063	12.904	14.588	4.9		
Tipranavir [37]	27.923	16.549	18.736	7	6.9(D)	
Toddacoumaquinone [22]	28.005	19.471	7.079	3.6		
Tomentosolic acid [21]	-0.003	8.259	18.830	6.1		
Triterpenoids [42]	84.022	40.515	-11.814	3.9		

(M), (I): molecular and ionized compounds; MIFS, MIHB, MIES, MUVW: Molecular interaction energy value of the final (optimized) structure, hydrogen bonding, electrostatic and van der Waals interaction (unit: kcal·mol⁻¹)

*log*P* and p*K*_a from PubChem: D(Drug Bank), E(EPA DSSTox), H(Hansch log*P*), S(Sangster), Ch(ChEMBL), H.S. (Hazardous substance data bank)

The binding inhibitor candidates were *m*-carboxyl-*L*-tyrosine, citric acid, and the citric acid glycosides, ferulic acid, gallic acid, glycyrrhizic acid, ibuprofen, lactic acid, malic acid, mefenamic acid, nalidixic acid, and naproxen [20], modified PF07321332, and modified galocatechin gallate [15], and 2-Hydroxypropane-1,2,3-tricarboxylic acid. Only acidic compounds were repulsed from ACE-2. The modification of the phenolic hydroxy group or a cyano group to the carboxy group may avoid the adsorption at the contact site of ACE-2. However, this study did not analyze the binding affinity of monoclonal antibodies due to their

uncertain stereo structures in physiological conditions.

Further study is required for the proposed compound to predict the toxicity and the docking with SARS-CoV-2 protein and whether the new compounds may block the multiplication or not. The latter analysis requires a supercomputer. A new type of designed multiplex SARS-CoV-2 vaccine was proposed. The universal adjuvant-free nano-vaccine platform by clustered regularly interspaced short palindromic repeats engineering of bacteriophage T4 in which multiple targets can be incorporated into a single-phase scaffold to rapidly generate various vaccine candidates against any emerging pathogen during epidemic or pandemic situations [47]. The overall adjusted hazard ratio for SARS-CoV-2 infection was 0.47 and 0.51 after previous natural infection versus Pfizer and Moderna vaccination [49]. We have to make multi approaches to control coming new viruses.

4. Conclusion

Omicron BA.2 valiant demonstrated the highest binding strength with ACE-2 among various variants, including Delta valiant; however, Covid-19 changed the strategy, and it changed to a few mutations of Omicron BA.4 and BA.5 variants to enhance the multiplication; even the Omicron BA.4 and BA.5 variants' binding strength was weakened. The new variants, Omicron BQ.1 and BQ.1.1's binding strength, was also weakened; however, these variants are replacing Omicron BA.4 and BA.5 by multiplication. The candidate inhibitors for blocking the S-RBS and ACE-2 binding should be carboxy compounds repulsed from ACE-2 because several acidic amino acids exist at the ACE-2 contact site. The steric hindrance and the number of basic amino acids of variants affect the binding affinity. In the Omicron virus multiplication process, supplying excess basic amino acids is required. The "Healthy eating" report presented the regional food habitude, suggesting transmissibility and mortality are very high in certain countries. Excess eating of dairy and animal protein seems to relate to the urgent problem.

References

1. Editorial, Covid-19, a pandemic or not?, www.thelancet.com/infection, 20 (2020) 383, [http://doi.org/10.1016/s1473-3099\(20\)30180-8](http://doi.org/10.1016/s1473-3099(20)30180-8)
2. R. Horton, Offline: Covid-19 is not a pandemic, www.thelancet.com, 396(2020)874. Richard.horton@lancet.com
3. R.H. Shmerling, is the Covid-19 pandemic over, or not?, Harvard Health Publishing, October 26, 2022
4. E. Topol, An optimistic outlook, Ground Truths, Daily pandemic update #6, November 7, 2022, erictioik@substack.com
5. European Centre for Disease Prevention and Control; SARS-CoV-2 variants of dashboard 10 Nov. 2022. <http://www.ecdc.eu/en/covid-19/variant-concern>
6. M. Scudellari, How SARS-CoV-2 infects cells – and why Delta is so dangerous, Nature 2021) 595, 640-644, <https://doi.org/10.1038/d41586-021-02039-y>
7. M. Prillaman, Prior omicron infection protects against BA.4 and BA.5 variants, Nature News 21 July (2022), Doi: <https://doi.org/10.1038/d41586-022-01950-2>
8. E.Topol, The BA.5 story, The takeover by this omicron sub-variant is not pretty, Ground Truths, November 8, 2022.
9. A. Tuekprakhon, R. Nutalai, A. Dijokaite-Guraliu, D. Zhou, H.M. Ginn, M. Selvaraj, C. Liu, A.J.

- Mentzer, P. Supasa, H.M.R. Duyvesteyn, R. Das, D. Skelly, T.G. Ritter, A. Amini, S. Bibi, S. Adele, S.A. Johnson, B. Constantinides, H. Webster, N. Temperton, P. Klenerman, E. Barnes, S.J. Dunachie, D. Crook, A.H. Pollard, T. Lambe, P. Goulder, N.G. Paterson, M.A. Williams, D.R. Hall. E.E. Fry, J. Huo, J. Mongkolsapaya, J. Ren, D.I. Stuart, G.T. Screaton, Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum, *Cell*, 185 (2022) 2422-2433.e13. doi:10.1016/j.cell.2022.06.005. Epub 2022 Jun 9]
10. D.J. Sheward, C. Kim, J. Fischbach, S. Muschiol, R.A. Ehling, N.K. Bjorkstrom, G.B.K. Hedestam, S.T. Reddy, J. Albert, T.P. Peacock, B. Murrell, Evasion of neutralizing antibodies by omicron sublineage BA.2.75, *Lancet Infect Dis* 2022, Sept 1 (2022), [https://doi.org/10.1016/S1473-3099\(22\)00524-2](https://doi.org/10.1016/S1473-3099(22)00524-2).
 11. O. Stauffer, K. Gupta, J.E.H. Bucher, F. Kohler, C. Sigl, G. Singh, K. Vasileiou, A.Y. Relimpio, M. Macher, S. Fabritz, H. Dietz, E.A.C. Adam, C. Schaffitzel, A. Ruggieri, I. Platzman, I. Berger, J.P. Spatz, Synthetic virions reveal fatty acid-coupled adaptive immunogenicity of SARS-CoV-2 spike glycoprotein, *Nature Communications*, 13 (2022) 868, <https://doi.org/10.1038/s41467-022-28446-x>
 12. Y. Hu, E.M. Lewandowski, H. Tan, X. Zhang, R.T. Morgan, X. Zhang, L.M.C. Jacobs, S.G. Bitler, M.V. Gongora, J. Choy, X. Deng, Y. Chen, J. Wang, bioRxiv preprint doi: <https://doi.org/10.1101/2022.06.28.497978>
 13. B. Doctrow, How COVID-19 variants evade the immune response, *NIH Research Matter*, June 8, (2021).
 14. P. Han, L. Li, S. Liu, Q. Wang, D. Zhang, Z. Xu, P. Hana, X. Li, Q. Peng, C. Su, B. Huang, D. Li, R. Zhang, M. Tian, L. Fu, Y. Gao, X. Zhao, K. Liu, J. Qi, G. Gao, P. Wang, Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2, *Cell*, 185 (2022) 630-640. <https://doi.org/10.1016/j.cell.2022.01.001>
 15. T. Hanai, Quantitative in silico analysis of SARS-CoV-2 S-RBD omicron mutant transmissibility, *Talanta*, 240 (2022) 123206, <https://doi.org/10.1016/j.talanta.2022.123206>
 16. M. Kozlov, Omicron overpowers key COVID antibody treatments in early tests, *Nature* (2021), Dec 21, <https://doi.org/10.1038/d41586-021-03829-0> (Sotrovimab, DXP-604).
 17. D. Yamasoba, Y. Kosugi, I. Kimura, S. Fujita, K. Uriu, J. Ito, K. Sato, Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies, *www.thelancet.com/infection*, Vol22, July (2022), 942, [https://doi.org/10.1016/S1473-3099\(22\)00365-6](https://doi.org/10.1016/S1473-3099(22)00365-6)
 18. M. Hentzien, B. Autran, I. Pitoh, Y. Yazdanpanah, A. Calmy, A monoclonal antibody stands out against omicron subvariants: a call to action for wider access to Bebtelovimab, *www.thelancet.com/infection* 22, Sept (2022), [https://doi.org/10.1016/S1473-3099\(22\)00495-9](https://doi.org/10.1016/S1473-3099(22)00495-9)
 19. X. Zhu, D. Mannar, S.S. Srivastava, A.M. Berezuk, J.-P. Demers, J.M. Saville, K. Leopold, W. Li, D.S. Dimitrov, K.S. Tuttle, S. Zhou, S. Chittori, S. Subramaniam, Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies, *PloS Biol.* 19 (2021) pp. 1-12: e3001237, <http://doi.org/10.1371/journal.pbio.3001237>
 20. T. Hanai, SARS-CoV-2 transmissibility and the protein structures, *HYAKUMANBEN TUSHIN*, 181, (2021) pp. 4-12, (in Japanese), & T. Hanai, Covid-19 transmissibility and food habitude, *HYAKUMANBEN TUSHIN*, 182 (2021) 5-7, (in Japanese), <http://www.emeritusclub.jp>, T. Hanai, Quantitative analysis of SARS-CoV-2 variants transmissibility, & S-RBD and ACE-2 docking inhibitors: T. Hanai, (Ed.) *Quantitative in silico analytical chemistry* (2021) pp. 153-156, & 157-159. <http://www.hanai-toshihiko.net> (in English).
 21. S. Vardhan, S.K. Sahoo, Exploring the therapeutic nature of limonoids and triterpenoids against SARS-CoV-2 by targeting nsp13, nsp14, and nsp15 through molecular docking and dynamics simulations, *J. Traditional and Complementary Medicine*, 12 (2022) 44-54.
 22. C.S. Kumar, D. Ali, S. Alarifi, S. Radhakrishnan, I. Akbar, *J. Inf. Pub. Health*, 13 (2020) 1671-1677, <http://doi.org/10.1016/j.jiph.2020.09.002>
 23. C. Vidoni, A. Fuzimoto, A. Ferraresi, C. Isidoro, Targeting autophagy with natural products to prevent SARS-CoV-2 infection, *J. Traditional and Complementary Medicine* 12 (2022) 55-68.
 24. A. Swargiary, S. Mahmud, A. Saleh, Screening of phytochemicals as a potent inhibitor of 3-chymotrypsin and papain-like proteases of SARS-CoV-2: an in silico approach to combat Covid-19, *J. Biomol. Struct. Dynamics*, (2020) 1-15, doi: 10.1080/07391102.2020.1835729
 25. A.N. El-Hoshoudy, Investigating the potential antiviral activity drugs against SARS-CoV-2 by molecular docking simulation, *L. Mol. Liq.* 318 (2020) 113968, pp.19, <http://doi.org/10.1016/j.molliq.2020.11.3968>
 26. M. Shah, H.G. Woo, Omicron: A heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potentially escapes approved COVID-19 therapeutic antibodies, *bioRxiv* (2021), preprint doi:

- <http://doi.org/10.1101/2021.12.04.471200>
27. S. Assadiasl, Y. Fatanhi, B. Moshamovahed, B. Mohebbi, N.H. Nickname, Baricitinib: From rheumatoid arthritis to Covid-19, *J. Clin. Pharmacol.* 2021, June, 12 (2021) 1-17: DOI: 10.1002/JCPH.1874
 28. H. Ledford, Hundreds of Covid trials could provide a deluge of new drugs, *Nature* 603 (2022) 25-27 <https://doi.org/10.1038/d41586-022-00562-0>
 29. Z. Wang, L. Yang, Turning the tide; natural products and natural-product-inspired chemicals as potential counters to SARS-Cov-2 infection, *Front. in Pharmacol.* 11 (2020) 1-12. doi: 10.3389/fphar.2020.01013
 30. G. Jimenez-Avalos, A.P. VargasRuiz, N.E. Delgado-Pease, G.E. Olivos-Ramirez, P. Sheen, M. Fernandez-Diaz, M. Quiliano, M. Zimic, Covid-19 Working group in Peru, Comprehensive virtual screening of 4.8K flavonoids reveals novel insights into allosteric inhibition of ASRS-CoV-2 M_{pro}, *Scientific Reports*, 1115452 (2021) 1-18. www.nature.com/scientificreports, doi.org/10.1038/s41598-021-94951-6
 31. M. Saleh, J. Gabriels, D. Chang, B.S. Kim, A. Mansoor, E. Mahmood, P. Maller, H. Ismail, B. Goldner, J. Willner, S. Beldner, R. Mitra, R. John, J. Chinitz, N. Skipitaris, S. Mountantonakis, L.M. Epstein, Effect of chloroquine, hydroxychloroquine, and Azithromycin on the corrected Q.T. interval in patients with SARS-CoV-2 infection, *Circ. Arrhythm. Electrophysiol.* 13 (2020) 496-504, e008662, doi:10.1161/CIRCEP.120.008662
 32. S. Boopathi, A.B. Poma, P. Kolandaivel, Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment, *J. Biomol. Struc. Dyn.* (2020) 1-10, doi: 10.1080/07391102.2020.1758788
 33. S.H. Basha, Coronavirus drugs – a brief overview of past, present and future, *J. PeerScentist*, 2 (2020) e1000013. <http://journal.peerscientist.com>, pp.16
 34. E.J. Niesor, G. Boivin, E. Rheume, R.V. Shi, V. Lavoie, N. Goyette, M-E. Picard, A. Perez, F. Laghrissi-Thode, J.-C. Tardif, Inhibition of the 3CL protease and SARS-CoV-2 replication by dalcetrapib, *ACS Omega*, 6 (2021) 25, 16584-16591, doi.org/10.1021/acsomega.1c01797
 35. Z. Qiao, H. Zhang, H.F. Ji, Q. Chen, Computational view toward the inhibition of SARS-CoV-2 spike glycoprotein and the 3CL protease, *Communication*, 8 (2020) 53-61; doi.0.3390/computation8020053
 36. L.M. Jarvis, Dexamethasone could help in severe Covid-19; the old, inexpensive steroid appears to save lives in a large U.K. trial, *C&EN*, (2020) June 22, p.3
 37. P. Indu, M.R. Rameshkumar, N. Arunagirinathan, N.A. Al-Dhahi, M.V. Arasu, S. Ignacimuthu, Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent R.N.A. polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach, *J. Inf. Pub. Health*, 13 (2020) 1856-186, <http://doi.org/10.1016/j.jiph.2020.10.015>
 38. U. Agrawal, T. Raju, Z.F. Udawadia, Favipiravir: A new and emerging antiviral option in Covid-19, *Med. J. Armed Forces India*, 76(4) (2020) 370-376, doi: 10.1016/j.mjfi.2020.08.004
 39. L.D. Manzanara-Meza, O. Medina-Contreras, SARS-Cov-2 and influenza: a comparative overview and treatment implications, *Bol. Med. Hosp. Infant Mex.* 77(5) (2020) 262-273. doi: 10.24875/bmhim.20000183.
 40. C-R. Wu, W-C. Yin, Y. Jiang, H.E. Xu, Structure genomics of SARS-CoV-2 and its omicron variant: drug design templates for Dovid-19, *Acta Pharm. Sinica*, (2022), <https://doi.org/10.1038/s41401-021-00851-w>
 41. D.C. Hall Jr. H-F. Ji, A search for medications to treat COVID-9 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease, *Travel med. Inf. Disease*, 35 (2020) 101646, pp.3, <http://doi.org/10.1016/j.tmaid.2020.101646>
 42. S. Vardhan, S.K. Sahoo, Exploring the therapeutic nature of limonoids and triterpenoids against SARS-CoV-2 by targeting nsp13, nsp14, and nsp15 through molecular docking and dynamic simulations, *J. Traditional and Complementary Medicine*, 12 (2022) 44-54. <http://doi.org/10.1016/j.jtcme.2021.12.002>
 43. B. Halford, What is oleandrin, the compound touted as a possible COVID-19 treatment? Scientists warn that the natural botanical product is unproven and could have lethal side effects, *C&EN*, Aug.31,(2020) 6
 44. M. Alfaro, I. Alfaro, C. Angle, Identification of potential inhibitors of SARS-CoV-2 papain-like protease from tropane alkaloids from *Schizanthus porridge*: A molecular docking study, *Chem. Phy. Let.* 761 (2020) 138068 pp.1-10. <http://doi.org/10.1016/j.cplett.2020.138068>
 45. M.B.S. Al-Shuhaib, H.O. Hashim, J.M.B. Al-Shuhaib, D.H. Obayes, Atrecanin of *Laurus nobilis* is a new novel inhibitor of SARS-CoV-2 main protease with highly desirable drug-likeness, *J. Biomol. Struc. Dynamics* (2022) 13, <https://doi.org/10.1080/07391102.2022.2030801>
 46. S. Yuan, X. Yin, X.Z. Meng, J. Chan, Z-W. Ye, L. Riva, L. Pache, C.C-Y. Chan, P.M.Lai, C. Chan, V. Poon, N. Matsunaga, Y. Pu, C-K. Yuen, J. Cao, Liang, T. Kaiming, S. Li, Y. Du, Sheng, X. Wan, S. K-H. Sze, Z. Jinxia, H. Chu. R.K-H. Kok, K. To, D-Y. Jin, R. Sun, S. Chanda, K-Y. Yuen, Clofazimine broadly inhibits coronaviruses, including SARS-CoV-2. *Nature* 593 (2021) 418-423. <https://doi.org/10.1038/s41586-021-03431-4>
 47. J. Zhu, N. Ananthaswamy, S. Jain, H. Batra, W-C. Tang, D.A. Lewry, M.I. Richards, S.A. David, P.B. Kilgore, [...], V.B. Rao, A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering, *Science Advantages*, 7, No. 37 (2021)

DOI: 10.1126/sciadv.abh1547

48. Z. Xu, L. Yang, X. Zhang, Q. Zhang, Z. Yang, Y. Liu, S. Wei, W. Liu, Discovery of potential flavonoid inhibitor against COVID-19 3CL proteinase based on virtual screening strategy, *Front. Mol. Biosci.* 29 Sept (2020), <https://doi.org/10.3389/fmolb.2020.556491>
49. H. Chemaitelly, H.H. Ayoub, S. AlMukdad, P. Coyle, P. Tang, H.M. Yassine, H.A. Al-Khatib, M.K. Smatti, M.R. Hasan, Z. Al-Kanaani, E. Al-Kuwari, A. Jeremijenko, A.H. Kaleeckal, A.N. Latif, R.M. Shaik, H.F. Abdul-Rahim, G.K. Nasrallah, M.G. Al-Kuwari, A.A. Butt, H.E. Al-Romaihi, M.H. Al-Thani, A. Al-Khal, R. Bertollini, L.J. Abu-Raddad, Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study, *Lancet Microbe* 2022, pp.12, [http://doi.org/10.1016/S2666-5247\(22\)00287-7a](http://doi.org/10.1016/S2666-5247(22)00287-7a)

Highlights

- Quantitative *in silico* analysis of Covid-19 variants (BA.4, BA.5, BA.2.75, BQ.1, BQ.1.1) was performed to analyze their transmissibility as additional analysis of older variants, alpha - delta, BA.1, and BA.2.
- The calculated binding affinity was related to their transmissibility up to BA.1 and BA.2.
- Variants (BA.4, BA.5, BQ.1, BQ.1.1) supposed to be escaping neutralization exhibited weak binding affinity with ACE-2.
- The mutation to basic amino acids enhanced their transmissibility.
- The proposed treatment medicines did not work in blocking the S-RBD and ACE-2 binding. A further modification was proposed.

Declaration of interest statement

Acknowledgments

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interests

I have not found any reports about quantitative analysis of the transmissibility of Covid-19 variants based on *in silico* analysis, except my previous report in Talanta.